» Articles » PMID: 28375739

Mito-Apocynin Prevents Mitochondrial Dysfunction, Microglial Activation, Oxidative Damage, and Progressive Neurodegeneration in MitoPark Transgenic Mice

Abstract

Aims: Parkinson's disease (PD) is a neurodegenerative disorder characterized by progressive motor deficits and degeneration of dopaminergic neurons. Caused by a number of genetic and environmental factors, mitochondrial dysfunction and oxidative stress play a role in neurodegeneration in PD. By selectively knocking out mitochondrial transcription factor A (TFAM) in dopaminergic neurons, the transgenic MitoPark mice recapitulate many signature features of the disease, including progressive motor deficits, neuronal loss, and protein inclusions. In the present study, we evaluated the neuroprotective efficacy of a novel mitochondrially targeted antioxidant, Mito-apocynin, in MitoPark mice and cell culture models of neuroinflammation and mitochondrial dysfunction.

Results: Oral administration of Mito-apocynin (10 mg/kg, thrice a week) showed excellent central nervous system bioavailability and significantly improved locomotor activity and coordination in MitoPark mice. Importantly, Mito-apocynin also partially attenuated severe nigrostriatal degeneration in MitoPark mice. Mechanistic studies revealed that Mito-apo improves mitochondrial function and inhibits NOX2 activation, oxidative damage, and neuroinflammation.

Innovation: The properties of Mito-apocynin identified in the MitoPark transgenic mouse model strongly support potential clinical applications for Mito-apocynin as a viable neuroprotective and anti-neuroinflammatory drug for treating PD when compared to conventional therapeutic approaches.

Conclusion: Collectively, our data demonstrate, for the first time, that a novel orally active apocynin derivative improves behavioral, inflammatory, and neurodegenerative processes in a severe progressive dopaminergic neurodegenerative model of PD. Antioxid. Redox Signal. 27, 1048-1066.

Citing Articles

exacerbates glucocorticoid stress hormone-induced tau pathology via mitochondrial dysfunction.

Yu Q, Du F, Goodman J, Waites C bioRxiv. 2025; .

PMID: 39974942 PMC: 11838549. DOI: 10.1101/2025.02.03.636364.


Ketone ester-enriched diet ameliorates motor and dopamine release deficits in MitoPark mice.

Mahajan V, Nadel J, King M, Pawlosky R, Davis M, Veech R Eur J Neurosci. 2024; 60(11):6875-6890.

PMID: 39528410 PMC: 11612846. DOI: 10.1111/ejn.16601.


PET Imaging with [F]ROStrace Detects Oxidative Stress and Predicts Parkinson's Disease Progression in Mice.

Zhu Y, Kohli N, Young A, Sheldon M, Coni J, Rajasekaran M Antioxidants (Basel). 2024; 13(10).

PMID: 39456479 PMC: 11504722. DOI: 10.3390/antiox13101226.


Mitochondrial disorders leading to Alzheimer's disease-perspectives of diagnosis and treatment.

Pszczolowska M, Walczak K, Miskow W, Mroziak M, Chojdak-Lukasiewicz J, Leszek J Geroscience. 2024; 46(3):2977-2988.

PMID: 38457008 PMC: 11009177. DOI: 10.1007/s11357-024-01118-y.


Mitochondria in Alzheimer's Disease Pathogenesis.

Reiss A, Gulkarov S, Jacob B, Srivastava A, Pinkhasov A, Gomolin I Life (Basel). 2024; 14(2).

PMID: 38398707 PMC: 10890468. DOI: 10.3390/life14020196.


References
1.
Lull M, Block M . Microglial activation and chronic neurodegeneration. Neurotherapeutics. 2010; 7(4):354-65. PMC: 2951017. DOI: 10.1016/j.nurt.2010.05.014. View

2.
Boone L, Meyer D, Cusick P, Ennulat D, Bolliger A, Everds N . Selection and interpretation of clinical pathology indicators of hepatic injury in preclinical studies. Vet Clin Pathol. 2005; 34(3):182-8. DOI: 10.1111/j.1939-165x.2005.tb00041.x. View

3.
Sloan M, Alegre-Abarrategui J, Wade-Martins R . Insights into LRRK2 function and dysfunction from transgenic and knockout rodent models. Biochem Soc Trans. 2012; 40(5):1080-5. DOI: 10.1042/BST20120151. View

4.
Finel M, Majander A, Tyynela J, de Jong A, Albracht S, Wikstrom M . Isolation and characterisation of subcomplexes of the mitochondrial NADH:ubiquinone oxidoreductase (complex I). Eur J Biochem. 1994; 226(1):237-42. DOI: 10.1111/j.1432-1033.1994.tb20046.x. View

5.
Simonyi A, Serfozo P, Lehmidi T, Cui J, Gu Z, Lubahn D . The neuroprotective effects of apocynin. Front Biosci (Elite Ed). 2011; 4(6):2183-93. PMC: 4049349. DOI: 10.2741/535. View